Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Open Label Study of DS-5573a in Japanese Patients With Advanced Solid Tumors
jRCT2080222535Phase 1
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jun 2014
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of DS-5573a in Non-hematologic malignancy, sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Safety of DS-5573a and Pharmacokinetics of DS-5573a.
02
Drugs
DS-5573a
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on jRCT2080222535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222535.